Assessment of Clinical Course and Treatment Responses in Our Patients with Immune Thrombocytopenia
Abstract
Objective: Immune thrombocytopenia (ITP) is an acquired thrombocytopenia resulting from autoantibodies against platelet antigens. In this study, we aimed to analyze demographics, clinical characteristics, and treatment responses in our patients with chronic ITP on follow-up.
Methods: This is a retrospective study. Data, including sociodemographic and laboratory data, treatments received, and response rates, were retrieved from patients’ electronic health records or paper charts.
Results: A total of 92 patients were included in the study, and 62 (67.4%) were females. The median age of study patients was 40 years (range: 18-81years). During follow-up, evidence of bleeding was detected in 35 patients. Gastrointestinal bleeding was observed in four patients, and intracranial bleeding in three patients. No statistically significant difference was found in response rates between methylprednisolone and dexamethasone (p=0.795) in the first-line treatment and between eltrombopag and splenectomy (p=0.502) in the second-line treatment. Patients undergoing splenectomy were more likely to develop thrombosis.
Conclusion: In this cohort of chronic ITP patients, the disease was more prevalent in females, with a median age of 40 years, and bleeding complications occurred in a substantial proportion of patients, including rare but serious events such as intracranial hemorrhage. No significant differences were observed in response rates between first-line treatments (methylprednisolone vs. dexamethasone) or second-line treatments (eltrombopag vs. splenectomy). However, splenectomy was associated with a higher risk of thrombosis. These findings highlight the need for individualized treatment decisions and emphasize that standardization of treatment strategies and follow-up duration is essential to better evaluate treatment responses and long-term outcomes in chronic ITP.
Keywords
Ethical Statement
References
- Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitions, and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386-93. doi:10.1182/blood-2008-07-162503.
- Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829-66. doi:10.1182/bloodadvances.2019000966.
- Godeau B, Chevret S, Varet B, Lefrère F, Zini JM, Bassompierre F, et al. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial. Lancet. 2002;359(9300):23-9.
- Cuker A. Transitioning patients with immune thrombocytopenia to second-line therapy: challenges and best practices. Am J Hematol. 2018;93(6):816-23. doi:10.1002/ajh.25092.
- Arnold DM. Bleeding complications in immune thrombocytopenia. Hematology Am Soc Hematol Educ Program. 2015;2015(1):237-42. doi:10.1182/asheducation-2015.1.237.
- Neunert C, Noroozi N, Norman G, Buchanan GR, Goy J, Nazi I, et al. Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review. J Thromb Haemost. 2015;13(3):457-64. doi:10.1111/jth.12813.
- Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood. 2001;97(9):2549-54. doi:10.1182/blood.V97.9.2549.
- Piel-Julian ML, Mahévas M, Germain J, Languille L, Comont T, Lapeyre-Mestre M, et al. Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults. J Thromb Haemost. 2018;16(9):1830-42. doi:10.1111/jth.14227.
- Loustau V, Debouverie O, Canoui-Poitrine F, Baili L, Khellaf M, Touboul C, et al. Effect of pregnancy on the course of immune thrombocytopenia: a retrospective study of 118 pregnancies in 82 women. Br J Haematol. 2014;166(6):929-35. doi:10.1111/bjh.12976.
- Wang L, Xu L, Hao H, Jansen G, Liu G, Li H, et al. First-line treatment of adult patients with primary immune thrombocytopenia: a real-world study. Platelets. 2020;31(1):55-61. doi:10.1080/09537104.2019.1572875.